ACVR2B Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population that disrupts the human ACVR2B gene within the HEK293T host background. This target-gene disruption model generates a heterogeneous pool of cells carrying diverse loss-of-function edits, providing a versatile tool for examining activin/myostatin-mediated pathways without the constraints of monoclonal isolation. The polyclonal format preserves population-level signaling responses, making it suitable for experiments requiring robust average readouts such as ligand stimulation assays, pathway profiling, and high-throughput screening.
HEK293T cells are human embryonic kidney epithelial derivatives immortalized with the SV40 large T-antigen, conferring high transfection efficiency and rapid proliferation. These attributes have established HEK293T as a standard workhorse for viral packaging, recombinant protein production, and CRISPR-based genome editing. The cell line expresses core components of the TGF-beta superfamily signaling machinery, enabling physiologically relevant dissection of ACVR2B-dependent transduction when the endogenous gene is disrupted.
ACVR2B encodes a transmembrane serine/threonine kinase receptor that functions as the primary type II receptor for activin A, activin B, myostatin (MSTN), GDF11, and BMP2/4. Ligand engagement promotes heterodimerization with type I receptors ALK4 (ACVR1B), ALK5 (TGFBR1), or ALK7 (ACVR1C), which phosphorylate downstream SMAD2 and SMAD3. Activated SMAD2/3 partner with SMAD4 to translocate into the nucleus and transcriptionally regulate target genes such as SERPINE1, ID1, and CCND2. The receptor complex interacts with immunophilin FKBP12 and adaptor SARA, fine-tuning signal amplitude. In parallel, non-SMAD routes including MAPK cascades modulate cellular outcomes such as proliferation, differentiation, and metabolic adaptation.
Within the HEK293T context, ACVR2B knockout eliminates endogenous responses to activins and myostatin, creating a clean background for structure?Cfunction analyses, receptor reconstitution studies, and pathway decoupling. Because HEK293T cells retain functional SMAD proteins and transcriptional reporters (e.g., CAGA-luciferase), the knockout enables precise measurement of signaling kinetics and ligand specificity. Researchers can compare wild-type versus knockout cells to attribute phenotypes directly to ACVR2B, while minimizing off-target pathway noise. This lack of a clonal bottleneck also preserves the typical heterogeneity of the parental HEK293T population, enhancing biological relevance for population-level assays such as phospho-signaling analysis and migration/invasion studies.
This product serves a broad range of research applications, including the study of muscle mass regulation, cancer cachexia, metabolic diseases, cardiomyopathies, and visceral heterotaxy. Representative assays include western blotting for phosphorylated SMAD2/3, RT-qPCR quantification of SERPINE1 induction, immunofluorescence monitoring of SMAD nuclear localization, and cell viability assays under ligand treatment. The polyclonal knockout cells are particularly suited for CRISPR validation, drug-target deconvolution, and ligand-activity screening. For further details or to discuss custom gene editing projects, please contact Ascent Research.
